newsmetry
rusign inget started
macro

Precigen shares sink 27% after hours as rival Inovio wins FDA approval

Precigen stock fell 27% after hours after the FDA approved Inovio's Voceryq for a rare airway disease Precigen already treats, Stocktwits reports.

published on Newsmetry
original source published

the same feed is available to bots and dashboards through the api. connect the api →

Newsmetry newsroom

what happened

Shares of Precigen (PGEN) fell 27% in extended trading on Friday after regulators cleared a competing therapy for recurrent respiratory papillomatosis (RRP), according to Stocktwits. The approved drug, Voceryq from Inovio Pharmaceuticals (INO), is a plasmid DNA immunotherapy designed to trigger an immune response against the HPV strains that cause wart-like growths in the airways, with the aim of reducing repeat surgeries.

The FDA granted accelerated approval on the basis of an open-label trial of 32 adults; among patients with a heavier surgery burden, 27% needed no operations in the first year. The agency said post-approval studies are required to confirm clinical benefit. Inovio's stock rose more than 300% after hours, while its other assets remain investigational.

Precigen already sells PAPZIMEOS, approved in August 2025 and its only approved product. It generated $3.4 million in net sales in 2025, and $74.7 million in the first half of 2026 out of total revenue of $78.2 million.

why it matters

For Precigen the news ends the sense of a single-player niche, since nearly all of its revenue comes from one drug. Investors will watch how quickly Inovio can bring Voceryq to market against an established product, and whether the trial data holds up in post-approval studies.

market impact

Precigen (PGEN): a rival approval pressures its shares; Inovio (INO): FDA approval supports its stock

  • Precigen shares (PGEN) pressure down — a direct rival threatens the position of its only approved drug
  • Inovio shares (INO) pressure up — first FDA approval gives its inaugural product a commercial foundation

tags

StockUnited States

instruments

PGENINO

sources

  1. PGEN Stock Craters 27% After-Hours After Rival Inovio's Rare Disease Drug Receives FDA Approval — Stocktwits, 30 October 2026 at 22:24 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗

related stories